Skip to main contentSkip to navigation
Sirius Investors

CPRX Stock: Catalyst Pharmaceuticals, Inc. Stock Price, Analysis & Insights

Get live CPRX stock price $31.35, comprehensive Catalyst Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time CPRX stock data and investment insights.

31.35
0.05%Today
CPRXCatalyst Pharmaceuticals, Inc. • NASDAQ Capital Market • Healthcare
Market Cap
3.84B
Volume
204.16K
52W High
32.56
52W Low
19.05

Loading chart data...

Catalyst Pharmaceuticals, Inc. (CPRX) Overview

Catalyst Pharmaceuticals, Inc. (CPRX) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, CPRX trades at $31.35 with a market capitalization of 3.84B . Over the past 52 weeks, CPRX has traded between $19.05 and $32.56 , with the current price positioned at approximately 91% of this range . The stock currently...

Key Takeaways

  • Operates in the Healthcare sector (Biotechnology)
  • Market cap: 3.84B
  • Current price: $31.35
  • 52-week range: $19.05 - $32.56
  • P/E ratio: 18.12

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals...

Company Information

CEO
Richard John Daly
Sector
Healthcare
Industry
Biotechnology
Employees
181

Contact Information

Address
355 Alhambra Circle
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Valuation metrics suggest potential value opportunity (P/E: 18.1)

Lower volatility stock (Beta: 0.74) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Catalyst Pharmaceuticals, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Catalyst Pharmaceuticals, Inc.
  • Investors should consider how Catalyst Pharmaceuticals, Inc. fits within their overall portfolio allocation

Market Cap

3.84B

P/E Ratio (TTM)

18.12

Beta

0.74

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.